Search

Displaying results 6431 - 6440 of 8696 in total
  1. Drug

    N-sulfoglucosamine sulfohydrolase recombinant

    go.drugbank.com/drugs/DB12722
    Investigational

    N-sulfoglucosamine sulfohydrolase recombinant is under investigation for the treatment of Mucopolysaccharidosis III and Sanfilippo Syndrome Type A (MPS IIIA).

  2. Drug

    Ganetespib

    go.drugbank.com/drugs/DB12047
    Investigational

    Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.

  3. Drug

    Motexafin gadolinium

    go.drugbank.com/drugs/DB05428
    Investigational

    It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells.

  4. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

  5. Drug

    KB-141

    go.drugbank.com/drugs/DB03176
    Experimental

    An anticholesteremic agent.

  6. Drug

    Tiocarlide

    go.drugbank.com/drugs/DB13608
    Experimental

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis
  7. Drug

    Epanolol

    go.drugbank.com/drugs/DB13757
    Experimental

    Epanolol is an beta blocker.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  8. Drug

    Transcrocetinate

    go.drugbank.com/drugs/DB05974
    Investigational

    Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.

  9. Drug

    Crenolanib

    go.drugbank.com/drugs/DB11832
    Investigational

    Crenolanib is under investigation for the treatment of Diffuse Intrinsic Pontine Glioma and Progressive or Refractory High-Grade Glioma.

    Categories: Receptor, Platelet-Derived Growth Factor alpha, antagonists & inhibitors, Receptor, Platelet-Derived Growth Factor beta, antagonists & inhibitors
  10. Drug

    BRG01

    go.drugbank.com/drugs/DB18173
    Investigational

    BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]